



Press release

Contact:

Torben Jörgensen, President and CEO

Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Uppsala October 17, 2008

Biotage AB Nomination Committee

A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB. The Nomination Committee shall, before the Annual General Meeting 2009, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, the determination of fees and matters pertaining thereto.

.

The members of the Nomination Committee are:

Björn Odlander, HealthCap

Karl Swartling, Investor Growth Capital

Carl Rosén, 2 AP-fonden

Ove Mattsson, Chairman of the Board

Shareholders wishing to submit a proposal for members of the Board of Directors may do so sending e-mail to the Chairman of the Board of Directors of Biotage AB at info@eu.biotage.com.

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com